Document Type
Article
Date of Original Version
5-1-2013
Department
Pharmacy Practice
Abstract
Ponatinib (Iclusig; Ariad Pharmaceuticals) is an oral tyrosine kinase inhibitor (TKI) that was approved by FDA on December 14, 2012, for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myelogenous leukemia (CML) that is resistant or intolerant to previous TKI therapy, and for Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (Ph+ALL).
Citation/Publisher Attribution
Brett Feret. (2013). Ponatinib: An oral tyrosine kinase inhibitor for the treatment of CML and Ph+ALL. Formulary, 169+. Retrieved from http://www.formularywatch.com/feature-articles/ponatinib-oral-tyrosine-kinase-inhibitor-treatment-chronic-myelogenous-leukemia-and-philadelphia
Author Manuscript
This is a pre-publication author manuscript of the final, published article.
Terms of Use
This article is made available under the terms and conditions applicable
towards Open Access Policy Articles, as set forth in our Terms of Use.